Orthofix International | OFIX - Selling And Administration Expenses


Orthofix International reported $130.35M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Accuray USD 124.78M 2.54M Dec/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 82.56M 1.99M Jun/2026
Dexcom USD 358.7M 9M Jun/2026
EDAP TMS EUR 12.92M 4.1M Mar/2026
Globus Medical USD 286.82M 10.95M Jun/2026
Inogen USD 43.77M 510K Jun/2024
Insulet USD 344.8M 27.6M Jun/2026
Integra LifeSciences USD 166.22M 12.01M Jun/2026
J&J USD 6.25B 168M Sep/2026
Medtronic 3.2B 141M Jun/2026
Mesa Laboratories USD 27.31M 380K Sep/2024
Orthofix International USD 130.35M 11.31M Dec/2025
Plus Therapeutics USD 4.26M 779K Mar/2026
Smith & Nephew USD 1.45B 29M Jun/2026
STAAR Surgical USD 45.14M 6.5M Jun/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 111.64M 3.45M Jun/2026
Teleflex USD 213.52M 12.5M Jun/2026
Veracyte USD 55.71M 4.87M Jun/2026
Zimmer Biomet Holdings USD 911.6M 61.7M Jun/2026